Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-11-17
Based on 1116 first isolates · ED · Febrile UTI / pyelonephritis · 2023-11-19 → 2024-11-17
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 81 % (79 %–83 %)
Not covered: Enterococcus faecalis (8 %), Escherichia coli (4 %), Staphylococcus aureus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
88 %
n = 88
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
84 %
n = 88
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
85 %
n = 88
ciprofloxacin CIP
trend · Escherichia coli
81 %
78 %
n = 88
ceftriaxone CRO
trend · Escherichia coli
80 %
77 %
n = 88
mecillinam MEC
trend · Escherichia coli not for this site
80 %
76 %
n = 88
trimethoprim TMP
trend · Escherichia coli not for this site
77 %
73 %
n = 88
75 %
73 %
n = 88
51 %
57 %
n = 88
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
13 %
n = 88
4 %
8 %
n = 88
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 88

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
4 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.